INVO Q3 revenue surges 314% to $974,894; clinics generate positive net income; merger with NAYA pending

INVO Fertility, Inc.

2023-Q3 EPS reported -$5.76 revenue$1,638,821

Revenue $974,894 (+314% YoY); pro forma revenue incl. full WFI quarter ~$1.5M (+534%).
Net loss $(1.2)M improved from $(2.5)M; pro forma net loss $(1.0)M.
Adjusted EBITDA $(0.6)M vs $(2.0)M; pro forma $(0.3)M; clinics profitable excluding corporate overhead.
Cash & equivalents $1.1M as of Sep 30, 2023.
Merger with NAYA Biosciences (all-stock) - closing conditions including shareholder approval and $5M+ PIPE not yet satisfied.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

INVO Fertility, Inc. reported financial results for the three months ended September 30, 2023.

Period: the three months ended September 30, 2023
Result: reported results

Exact text from the filing

On November 13, 2023, INVO Bioscience, Inc. (the “Company”) issued a press release announcing financial results for the period ended September 30, 2023. The text of the press release is furnished as Exhibit 99.1 to this current report.

View on SEC.gov

44 earnings releases filed in the last 30 days. Browse all earnings releases →

INVO Fertility, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-23-040500

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.